<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258930</url>
  </required_header>
  <id_info>
    <org_study_id>FNEIDAC-HZ-122-19</org_study_id>
    <nct_id>NCT04258930</nct_id>
  </id_info>
  <brief_title>Occlusion vs Standard Treatment for the Treatment of Herpes Zoster</brief_title>
  <official_title>Randomized Comparative Open Trial of Occlusive Therapy With a Hydrocolloid or Silicone Versus Conventional Drying Treatment for the Local Care of Acute Lesions Caused by Herpes Zoster.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition of occlusive dressings (hydrocolloids) or topical silicone
      gel in the treatment of shingles (herpes zoster). One third of the participants will receive
      a hydrocolloid occlusive dressing, one third will receive the topical silicone gel and one
      third will receive the current treatment of the rash consisting of drying solutions (soaks).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Herpes zoster (HZ), also known shingles, is a viral disease caused by the varicella-zoster
      virus. It is considered a local reactivation of varicella (chicken pox). The rash of herpes
      zoster is characterized by vesicles that appear following a single dermatome (the territory
      that is innervated by one spinal nerve). These vesicles may be very painful and cause
      discomfort due to draining and crusting. When a person becomes sick with shingles healthcare
      professionals prescribe systemic (oral) treatment with antivirals (e.g. acyclovir) and pain
      medication according to the type and severity. To treat the local lesions caused by shingles,
      over the centuries, patients have been treated with drying solutions and drying powders. This
      practice has been passed on through the years without any evidence supporting its
      effectiveness, in all likelihood due to the fact that the rash is self-limited to 2 to 3
      weeks. Recently, new evidence has shown that the vesicles that appear with the shingles rash
      are not superficial but involve deeper areas of the skin and should be considered partial
      thickness wounds. Since 1962, it has become clear that partial thickness wounds benefit from
      occlusive therapy (keeping wounds closed and avoiding drying) such as dressings and occlusive
      gels that keep the wound wet rather than allowing it to dry.

      In this clinical trial the investigators believe that given this information, using occlusive
      therapy with a hydrocolloid dressing or a silicone-based gel may heal the rash of herpes
      zoster, decrease pain and improve the quality of life, much faster than the treatment
      currently used of drying the area with powders and solutions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized comparative open trial comparing occlusive therapy with hydrocolloid dressings versus a silicone gel vs a drying solution (standard care) to treat the rash of herpes zoster.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days to achieve complete healing of cutaneous lesions.</measure>
    <time_frame>Evaluation at 10 days.</time_frame>
    <description>The total number of days from the beginning of the rash to the disappearance of all scabs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in pain score using the Zoster Brief Pain Inventory (ZBPI)</measure>
    <time_frame>Evaluation at baseline, 5 days, 10 days and 40 days.</time_frame>
    <description>Score reduction in the Zoster Brief Pain Inventory (ZBPI). It uses an 11-point Likert scale (0-10) to rate herpes zoster pain and discomfort for four different dimensions (worst, least, and average during the past 24 hours, and now) and herpes zoster pain and discomfort-related interference with seven items of activities of daily living and health: general activity, mood, walking ability, work, relations with others, sleep, enjoyment of life.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain reduction as per acetaminophen need</measure>
    <time_frame>Evaluation at 40 days.</time_frame>
    <description>Amount of acetaminophen taken in total for pain control through the duration of the trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the quality of life score as measured by the Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>Evaluation at baseline, 5 days, 10 days and 40 days.</time_frame>
    <description>Quality of life score improvement as measured by the Dermatology Life Quality Index (DLQI). There are 10 questions, covering the following topics: symptoms, embarrassment, shopping and home care, clothes, social and leisure, sport, work or study, close relationships, sex, treatment. Each question refers to the impact of the skin disease on the patient's life over the previous week. Each question is scored from 0 to 3, giving a possible score range form 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description and quantification of any side effect during the trial.</measure>
    <time_frame>Evaluation at baseline, 5 days, 10 days and 40 days.</time_frame>
    <description>Presence or absence of side effects of any of the above treatments.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Group A: Aluminum sulphate and calcium acetate drying soaks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A will receive 10 minute soaks every 8 hours with a solution prepared with aluminum sulphate and calcium acetate powder (Domeboro® (Advaita Pharmaceuticals, México)) diluted in 500 ml of clean cold water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Topical sterile silicone gel for wounds</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B will receive topical silicone sterile gel for wounds (Stratamed gel®, (Stratapharma, Switzerland)) applied every 8 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Hydrocolloid dressing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group C will apply an extra thin hydrocolloid dressing to all the open areas (Duoderm Extra Thin® (Convatec, USA)) with dressing changes every 48 to 72 hours depending on the amount of wound exudate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Aluminum sulphate and calcium acetate drying soaks</intervention_name>
    <description>Dilute one envelope of the powder in 500 ml of clean cold water and apply for 10 minutes every 8 hours until completely healed.</description>
    <arm_group_label>Group A: Aluminum sulphate and calcium acetate drying soaks</arm_group_label>
    <other_name>Domeboro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Topical sterile silicone gel for wounds</intervention_name>
    <description>Apply a thick layer of silicone gel to all open areas every 8 hours until completely healed.</description>
    <arm_group_label>Group B: Topical sterile silicone gel for wounds</arm_group_label>
    <other_name>Stratamed gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hydrocolloid dressing</intervention_name>
    <description>Apply enough hydrocolloid dressings to cover all open areas and change every 2 to 3 days once the dressing becomes saturated (starts to drain around the borders).</description>
    <arm_group_label>Group C: Hydrocolloid dressing</arm_group_label>
    <other_name>Duoderm Extra-thin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with clinical diagnosis of HZ confirmed by a certified dermatologist

          -  Patients having maximum 72 hours from the start of the first vesicle

          -  Older than 18 years

        Exclusion Criteria:

          -  Patients with dimethicone allergy

          -  Patients with hydrocolloid allergy

          -  Patients with acetaminophen allergy

          -  Patients with aluminium sulphate and calcium acetate allergy

          -  Patients with acyclovir allergy

          -  Pregnant women

          -  Breastfeeding women

          -  Unable to give informed consent

          -  Patients with signs of infection over the skin rash

          -  Patients with disseminated HZ

          -  Patients with hemorrhagic HZ

          -  Patients with complications such as pneumonia or encephalitis

          -  Patients unable to apply the treatment to the affected area

          -  Patients with HZ-associated keratitis

          -  Patients whose rash is located to hairy areas that may hinder occlusion with the
             hydrocolloid dressing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose Contreras-Ruiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Contreras-Ruiz, MD</last_name>
    <phone>+525540003000</phone>
    <phone_ext>6704</phone_ext>
    <email>dermayheridas@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adriana Lozano-Platonoff, MD</last_name>
    <phone>+525540003000</phone>
    <phone_ext>6704</phone_ext>
    <email>dralozanoplatonoff@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General Dr Manuel Gea González</name>
      <address>
        <city>Mexico</city>
        <state>DF</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Contreras-Ruiz, MD</last_name>
      <phone>+525540003000</phone>
      <phone_ext>6704</phone_ext>
      <email>dermayheridas@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Adriana Lozano-Platonoff, MD</last_name>
      <phone>+525540003000</phone>
      <phone_ext>6704</phone_ext>
      <email>dralozanoplatonoff@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Boivin G, Jovey R, Elliott CT, Patrick DM. Management and prevention of herpes zoster: A Canadian perspective. Can J Infect Dis Med Microbiol. 2010 Spring;21(1):45-52.</citation>
    <PMID>21358885</PMID>
  </reference>
  <reference>
    <citation>Bader MS. Herpes zoster: diagnostic, therapeutic, and preventive approaches. Postgrad Med. 2013 Sep;125(5):78-91. doi: 10.3810/pgm.2013.09.2703. Review.</citation>
    <PMID>24113666</PMID>
  </reference>
  <reference>
    <citation>Cohen JI. Clinical practice: Herpes zoster. N Engl J Med. 2013 Jul 18;369(3):255-63. doi: 10.1056/NEJMcp1302674. Review.</citation>
    <PMID>23863052</PMID>
  </reference>
  <reference>
    <citation>Coplan PM, Schmader K, Nikas A, Chan IS, Choo P, Levin MJ, Johnson G, Bauer M, Williams HM, Kaplan KM, Guess HA, Oxman MN. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004 Aug;5(6):344-56.</citation>
    <PMID>15336639</PMID>
  </reference>
  <reference>
    <citation>Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6.</citation>
    <PMID>8033378</PMID>
  </reference>
  <reference>
    <citation>Greenwood JE, Wagstaff MJ, Mackie IP, Mustoe TA. Silicone action in the open wound: a hypothesis. J Burn Care Res. 2012 Jan-Feb;33(1):e17-20. doi: 10.1097/BCR.0b013e31823e68cc.</citation>
    <PMID>22138810</PMID>
  </reference>
  <reference>
    <citation>HINMAN CD, MAIBACH H. EFFECT OF AIR EXPOSURE AND OCCLUSION ON EXPERIMENTAL HUMAN SKIN WOUNDS. Nature. 1963 Oct 26;200:377-8.</citation>
    <PMID>14087904</PMID>
  </reference>
  <reference>
    <citation>Karlsmark T, Goodman JJ, Drouault Y, Lufrano L, Pledger GW; Cold Sore Study Group. Randomized clinical study comparing Compeed cold sore patch to acyclovir cream 5% in the treatment of herpes simplex labialis. J Eur Acad Dermatol Venereol. 2008 Nov;22(10):1184-92. doi: 10.1111/j.1468-3083.2008.02761.x. Epub 2008 May 6.</citation>
    <PMID>18462303</PMID>
  </reference>
  <reference>
    <citation>Keegan DA. Reducing pain in acute herpes zoster with plain occlusive dressings: a case report. J Med Case Rep. 2015 Apr 25;9:89. doi: 10.1186/s13256-015-0560-5.</citation>
    <PMID>25907451</PMID>
  </reference>
  <reference>
    <citation>Lin PL, Fan SZ, Huang CH, Huang HH, Tsai MC, Lin CJ, Sun WZ. Analgesic effect of lidocaine patch 5% in the treatment of acute herpes zoster: a double-blind and vehicle-controlled study. Reg Anesth Pain Med. 2008 Jul-Aug;33(4):320-5. doi: 10.1016/j.rapm.2007.02.015.</citation>
    <PMID>18675742</PMID>
  </reference>
  <reference>
    <citation>Monk EC, Benedetto EA, Benedetto AV. Successful treatment of nonhealing scalp wounds using a silicone gel. Dermatol Surg. 2014 Jan;40(1):76-9. doi: 10.1111/dsu.12366. Epub 2013 Nov 25.</citation>
    <PMID>24267314</PMID>
  </reference>
  <reference>
    <citation>O'Brien L, Jones DJ. Silicone gel sheeting for preventing and treating hypertrophic and keloid scars. Cochrane Database Syst Rev. 2013 Sep 12;(9):CD003826. doi: 10.1002/14651858.CD003826.pub3. Review.</citation>
    <PMID>24030657</PMID>
  </reference>
  <reference>
    <citation>Patel AR, Romanelli P, Roberts B, Kirsner RS. Treatment of herpes simplex virus infection: rationale for occlusion. Adv Skin Wound Care. 2007 Jul;20(7):408-12. Review.</citation>
    <PMID>17620742</PMID>
  </reference>
  <reference>
    <citation>Patel AR, Romanelli P, Roberts B, Kirsner RS. Herpes simplex virus: a histopathologic study of the depth of herpetic wounds. Int J Dermatol. 2009 Jan;48(1):36-40. doi: 10.1111/j.1365-4632.2009.03788.x.</citation>
    <PMID>19126048</PMID>
  </reference>
  <reference>
    <citation>Pott FS, Meier MJ, Stocco JG, Crozeta K, Ribas JD. The effectiveness of hydrocolloid dressings versus other dressings in the healing of pressure ulcers in adults and older adults: a systematic review and meta-analysis. Rev Lat Am Enfermagem. 2014 May-Jun;22(3):511-20. Review. English, Portuguese, Spanish.</citation>
    <PMID>25029065</PMID>
  </reference>
  <reference>
    <citation>Tsai TF, Yao CA, Yu HS, Lan CC, Chao SC, Yang JH, Yang KC, Chen CY, White RR, Psaradellis E, Rampakakis E, Kawai K, Acosta CJ, Sampalis JS. Herpes zoster-associated severity and duration of pain, health-related quality of life, and healthcare utilization in Taiwan: a prospective observational study. Int J Dermatol. 2015;54(5):529-36. doi: 10.1111/ijd.12484. Epub 2014 Sep 10.</citation>
    <PMID>25209019</PMID>
  </reference>
  <reference>
    <citation>Uva L, Aphale AN, Kehdy J, Benedetto AV. Erosive pustular dermatosis successfully treated with a novel silicone gel. Int J Dermatol. 2016 Jan;55(1):89-91. doi: 10.1111/ijd.13066. Epub 2015 Sep 4.</citation>
    <PMID>26341747</PMID>
  </reference>
  <reference>
    <citation>WINTER GD. Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature. 1962 Jan 20;193:293-4.</citation>
    <PMID>14007593</PMID>
  </reference>
  <reference>
    <citation>Strauss SE, Oxman NM. Varicella and Herpes Zoster. In: Freedberg IM, Eisen AZ, Wolff K, Kopff A, et al. editors. Fitzpatrick´s dermatology in general medicine. New York, McGraw-Hill 1999, pp 2427-49.</citation>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
    <mesh_term>Calcium acetate</mesh_term>
    <mesh_term>Aluminum sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

